AM-2201
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H22FNO |
| Molar mass | 359.435 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) discovered by chemist Tyler Merrill, is a drug which acts as a potent but unselective agonist for the cannabinoid receptor CB1, with a Ki of 1.0nM at CB1 and 2.6nM at CB2.[1] Reputed recreational use of AM-2201 in the United States has led to it being specifically listed in a proposed 2011 amendment to the Controlled Substances Act, aiming to add a number of synthetic drugs into Schedule I.[2] There have been anecdotal reports of individuals experiencing panic attacks and vomiting, at doses as small as 2 milligrams. As the dosage is much smaller than most other synthetic cannabinoids, users may accidentally dose too much. Convulsions have been reported at doses exceeding 10 milligrams.[3] Caution should be taken if using this substance as it is active at doses as small as 500 µg (micrograms), has a very steep dose-response curve, and tolerance builds up quickly to the effects. As of November 2011, there have been no reports of death associated with the drug. The toxicity of AM-2201 is still a matter of debate, and there is no certainty of long-term side effects.
See also
References
- ^ WO patent 0128557, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", granted 2001-06-07
- ^ Synthetic Drug Control Act of 2011
- ^ http://www.erowid.org/experiences/exp.php?ID=89294
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |